Background: Lung cancer is one of the most common non-AIDS-defining malignancies among HIV-infected patients. Recent studies suggest that lung cancer risk is 3 to 4 times higher in HIV-infected patients than in uninfected persons after adjusting for other factors such as smoking intensity and duration. Methods: A retrospective chart review (2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)) was conducted in our institution. An abstraction form was used to compile data that included demographics, T-cell count, and viral loads before and at the time of diagnosis, comordibities, smoking, and use of alcohol and drugs. Results: A total of 16 patients were found. Of these, 11 (69%) patients were male and 5 (31%) female. The average age at diagnosis was 49 years (range 36-54). The Majority of patients were African American (90%). Their average CD4 counts before and at the time of diagnoses were 241 and 211 cells/mm 3 , respectively. Their viral loads before and at the time of diagnosis ranged from <48 to 437 000 and <48 to 590 760 copies/mL, respectively. Adenocarcinoma was found in 67% of cases. The majority of cases (85%) were detected at advanced stages (IIIB or IV). Smoking was found in 100% of cases (average of 15-20 pack/year history), alcohol use in 70% of cases, and drug abuse in 50%. Conclusions: Lung cancer is very common in HIV-infected populations. It tends to occur at a young age, and it is usually diagnosed at very advanced stages (IIIB or IV). The main risk factors found in our study were extensive smoking history, young age, male sex, and potentially prolonged immunosuppression. Based on these results, an attempt to construct a high-risk group index might not be appropriate due to the limited number of cases studied and the need for further evaluation of the length of immunosuppression and the real impact of HIV RNA viral load in the development of lung cancer.
Introduction
Lung cancer is one of the most common cancers worldwide. Recent reports indicate that it is responsible for approximately 1.1 million deaths (17.8%) of all cancers in 2000. 1 The incidence and mortality of lung cancer seems to be increased in HIV-positive populations. 2 Some studies have described the clinical characteristics of lung cancer in HIV-infected patients. Some factors, such as young age, smoking, HIV RNA viral load, use of intravenous drugs, and other comorbidites, have been identified for lung cancer development in these patients. 3 The clinical course in HIV-infected patients appears to be more aggressive, their survival shorter, and their response to treatment (surgery, radiotherapy, chemotherapy) suboptimal as compared to their non-HIV-infected counterparts. 4 This article describes the clinical characteristics of HIVpositive patients with lung cancer in an outpatient urban setting. Risk factors found in this retrospective study are also mentioned. Future steps to counteract this problem are discussed.
Lung cancer is one of the most common non-AIDS-defining malignancies among HIV-infected patients. 2, 5 Recent studies suggest that lung cancer risk is 3 to 4 times higher in HIVinfected patients than in uninfected persons after adjusting for other factors such as smoking intensity and duration. 4 One study calculated the incidence as 6.7/100 000 HIV-infected patients in the post-antiretroviral (ARV) era. 2 In a retrospective study of 6 HIV-infected patients with lung cancer, Kato et al 6 studied the clinical characteristics of lung cancer. All patients were male and current smokers. The authors found adenocarcinoma as the most prevalent type of cancer. In all, 70% of cases were diagnosed at advanced stages (IIIB and IV). The average T-cell count ranged from 52 to 432. The researchers found good outcomes after treatment with a combination of ARV drugs and lung cancer treatment.
In a retrospective study of 34 HIV-infected patients with lung cancer, Hakimian et al 7 found similar survival rates between HIV-positive patients with advanced non-small cell lung carcinoma and non-HIV-infected patients. Concomitantly, the authors found a survival advantage for HIV-positive patients treated with chemotherapy versus the same population not treated with chemotherapy (5.2 vs 2.1 months). Patients with a T-cell count >200 cells/mm 3 seem to have a better rate of survival compared to patients with low T-cell counts.
Cadranel et al 8 reviewed the characteristics of lung cancer in HIV-infected patients. Based on published literature, the authors found factors such as young age (45 years), extensive smoking history, intravenous drug use, advanced stage at presentation, and peripheral adenocarcinoma as the main features of this disease. The researchers found that HIV infection and its mutagenic role, T-cell count, and HIV viral load are factors in need of more research.
Lavole et al 4, 9 found the risk of lung cancer development to be higher in HIV-infected patients compared to non-HIVinfected populations. The median age at diagnosis was 45 years. The diagnosis was found to be locally advanced or metastatic in 75-90% of cases. The authors found a worse prognosis in HIV-positive populations. They indicated the need for more prospective studies involving the optimal treatment of lung cancer in HIV-infected populations.
Bazoes et al 10 discussed the role of immunosuppression and smoking in lung cancer and HIV infection. The authors pointed out that studies in transplant patients and HIV-infected patients revealed the presence of immunosuppression as a common factor for the development of malignancies. In this respect, the role of the HIV RNA viral load is unknown. Smoking might be a significant factor in HIV-infected patients even though the evidence is not conclusive. The authors also found the correlation between young age of lung cancer diagnosis in HIV-positive populations and the increased frequency of adenocarcinoma diagnosis since the latter disease tends to develop in young patients. The researchers concluded that antiretroviral therapy (ART) might not have a beneficial effect in outcomes of lung cancer.
Kirk et al (2007) 11 found factors such as pulmonary noninfectious diseases, asthma, and smoking as main variables related to increased lung cancer frequency in HIV-infected patients. The authors did not find a strong association among HIV viral load, T-cell count, and an increased risk of lung cancer. They identified HIV infection as an independent risk factor for lung cancer development.
It appears that all major cancer subtypes are equally increased (adenocarcinoma, squamous cell carcinoma, and small cell carcinoma), making the HIV-infected population a high-risk group. 2, 12 Adenocarcinoma has been the type most commonly found in the above mentioned reviews.
Risk Factors for Development of Lung Cancer
As in non-HIV-infected populations, the most significant risk factor for the development of lung cancer in HIV-infected populations is smoking; however, other factors have also been identified as risks for this group: potential oncogenic activity of the HIV virus, prolonged moderate or severe immunosuppression, and aging. 2, 4, 13 Other studies have suggested that men who have sex with men and intravenous drug users should also be included in the high-risk group. [3] [4] [5] 14 The role of non-tuberculous mycobacterial colonization/ infection in certain patients with lung cancer has been previously reported. [15] [16] [17] [18] These reports indicate that nontuberculous mycobacteriosis has been found in certain cases of advanced lung cancer in non-HIV-infected populations. Non-tuberculous mycobacterial infections appear to be bystanders of lung cancer, and the suspected oncogenic activity of colonization/infection of these mycobacteria has not been studied in HIV-infected patients. Engels et al 2 referred to 2 potential HIV-related immunologic mechanisms associated with lung cancer risk: the presence of chronic pulmonary inflammation and repeated infections. Therefore, even though no studies have detailed the association between non-tuberculous mycobacterial infection/colonization and lung cancer, the presence of chronic inflammation might predispose these patients to have a higher risk of lung cancer development.
In vitro studies have shown that tat (transactivator of transcription) gene product from HIV can increase the expression of the proto-oncogenes c-myc, c-fos, and c-jun and downregulate the tumor suppression gene p53 in lung adenocarcinoma cell lines. 13 The role of a possible increase in genomic instability in the increased risk of lung cancer among HIV-infected patients has been suggested by a study of 16 polymorphic markers on 8 chromosome arms frequently deleted in lung cancer. 4 This study pointed out that microsatellite instability was 6 times more frequent in the HIV-infected patients.
The relationship of chronic immunodepression to the excessive risk of lung cancer among HIV-infected patients is difficult to determine. It has been studied in transplant patients who share the same risk of lung cancer development independent of smoking. 2, 4 Lung cancer, however, may develop at any point in the course of HIV disease. 2, 4, [19] [20] [21] The role of prolonged immunosuppression before the start of ART has been linked to the development of lung cancer in HIV-infected patients. 4, 20, 21 Some studies have indicated that the risk may be maximal in periods immediately before AIDS and subsequent to an AIDS diagnosis. 2, 4, 21 Therefore, the presence of immunosuppression may not fully explain the behavior of certain lung cancers in HIV-infected patients. Furthermore, the risk of lung cancer has not been shown to be closely related to CD4 cell count or HIV viral load. 2 The role of ART with regard to lung cancer risk is controversial at this time. Despite improved immune function on ART, cancer immune surveillance is still inadequate in patients living with HIV. Histology type, staging, symptomatology, comorbidities, type of ARV drugs used, associated risk factors such as smoking, alcohol and drug use, and presence of chronic lung infections were also documented.
Results
A total of 16 patients with HIV infection also had lung cancer. Eleven of those patients were male (69%) and 5 female (31%). The average age at diagnosis was 49 (range 36-54) years. The majority of patients were African American (90%). Their average CD4 counts before and at the time of diagnosis were 241 and 211 cells/mm 3 , respectively. Their viral loads before and at the time of diagnoses ranged from <48 to 437 000 and <48 to 590 760 copies/mL, respectively.
In relation to the histology type, adenocarcinoma was found in 10 (67%) cases. With 1 exception, all of the remaining cases were squamous cell carcinoma cases (26%). There was 1 (7%) case of small cell carcinoma.
The following were the most common symptoms: chronic intermittent chest pain (75%), weight loss (75%), chronic cough (80%), shortness of breath (50%), and hemoptysis (30%). The most common comorbidities found were pneumonia (85%), chronic obstructive pulmonary disease (65%), and hepatitis B or hepatitis C (50%). Table 1 shows the characteristics of HIV-infected patients with lung cancer in our cohort.
In relation to laboratory values the mean creatinine was 0.87, mean albumin was 2.41, and the mean calcium value was 8.38. A total of 12.5% of patients presented with abnormal liver enzymes.
The majority of cases (85%) were detected at advanced stages (IIIB or IV). A total of 75% of patients presented with metastases and/or complications. Approximately 37.5% of patients were treated with a combination of surgery, radiotherapy, and chemotherapy; 18.75% were treated with both surgery and radiotherapy; and 43.75% were treated with palliative interventions (either chemotherapy or radiotherapy).
In terms of risk factors, smoking was found in 100% of cases (average of 15-20 pack-year history), alcohol use in 70% of cases, and drug abuse in 50%.
All patients were on ART at the time of diagnosis and afterward. The most common backbone regimen used was a combination of nucleoside analogues and nonnucleoside analogues (67%). In only 1 case, there was an association of lung cancer with non-tuberculous mycobacterial infection (Mycobacterium avium complex in sputum colonization).
Discussion
Lung cancer is a common neoplasm in HIV-infected populations. In fact, it appears to be the third most common non-AIDSdefining malignancy. In this study, we report retrospective findings of HIV-infected patients affected with lung cancer in our clinic.
We found factors such as young age, male gender, and extensive smoking history to be important for lung cancer development. Adenocarcinoma was the most common type found in our study. Interestingly smoking has not been related in the pathogenesis of adenocarcinoma. The majority of the patients were diagnosed at advanced stages of the disease (IIIB and IV). These 2 findings are in positive correlation with the findings from other reports.
The role of immunosuppression has not been clearly defined. The results of our study suggest that immunosuppression may not play a role in lung cancer development. A nadir in T-cell count and length of immunosuppression may be important to take into consideration. The role of HIV RNA viral load is still undefined. Our results, with the exception of few cases, did not show a correlation at all between HIV RNA viral load and lung cancer.
Based on risk factors found in this and other studies, young age, extensive smoking history, and perhaps prolonged immunosuppression (defined as a T-cell count <200 cells/mm 3 for an extensive period of time) may significantly affect the development of lung cancer in HIV-infected patients. The frequency of adenocarcinoma in this cohort of patients is not explained by smoking exposure, therefore other explanations need to be investigated. This finding is in accordance with other reports from the literature. 2,5,20 
Limitations
This study had certain limitations that need to be taken into account. It is a retrospective analysis with only a few cases that might have an impact on the statistical analysis and generalization of results. Another potential pitfall might be the lack of outcome information (mortality), but this was not the main goal of the current study.
Conclusions
Lung cancer is very common in HIV-infected populations. It tends to occur at a young age (average age of 45 according to certain studies), and it is usually diagnosed at very advanced stages (IIIB or IV). The main risk factors seem to be extensive smoking history, young age, male sex, and potentially prolonged immunosuppression. These findings need further evaluation in studies involving a greater number of patients to determine the impact.
Based on these results, an attempt to construct a high-risk group index might not be appropriate due to the limited number of cases studied and the need for further evaluation of length of immunosuppression and the real impact of HIV RNA viral load in the development of lung cancer.
Patients with high-risk factors such as extensive smoking history, prolonged immunosuppression, and presence of HIV RNA in plasma may need to undergo screening tests to detect lung cancer in early stages.
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